Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.

Mayo Clinic proceedings - 1 Jul 2017

Yogarajah Meera, Tefferi Ayalew

Abstract excerpt

Myeloproliferative neoplasms (MPNs) operationally include essential thrombocythemia, polycythemia vera, primary myelofibrosis (PMF), and prefibrotic PMF. All 4 MPN variants might progress into blast-phase disease (MPN-BP). For essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to IDH2 gene
Share to RUNX1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SRSF2 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myeloproliferative Disorders

Share to Risk Factors

Source

Identifiers

PMID: 28688466
DOI: 10.1016/j.mayocp.2017.05.010

Genes

SRSF2
IDH2
RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.PMID 28688466Read ↗

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic OptionsSemantic proximity Read ↗

Accelerated and blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.Semantic proximity Read ↗

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Semantic proximity Read ↗

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosisSemantic proximity Read ↗

Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasmSemantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.